{"id":63076,"date":"2026-05-08T01:03:24","date_gmt":"2026-05-07T23:03:24","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/asset-value-investors-avi-urges-rohto-pharmaceutical-to-focus-on-core-businesses-and-engage-more-constructively-with-shareholders\/"},"modified":"2026-05-08T01:03:24","modified_gmt":"2026-05-07T23:03:24","slug":"asset-value-investors-avi-urges-rohto-pharmaceutical-to-focus-on-core-businesses-and-engage-more-constructively-with-shareholders","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/asset-value-investors-avi-urges-rohto-pharmaceutical-to-focus-on-core-businesses-and-engage-more-constructively-with-shareholders\/","title":{"rendered":"Asset Value Investors (AVI) Urges Rohto Pharmaceutical to Focus on Core Businesses and Engage More Constructively with Shareholders"},"content":{"rendered":"
\n

LONDON–(BUSINESS WIRE)–Asset Value Investors Limited (\u201cAVI\u201d) today announced an update to its public campaign regarding Rohto Pharmaceutical Co., Ltd. (TSE: 4527, \u201cRohto\u201d), as a follow-up to its ongoing campaign, \u201cAwakening Rohto\u201d<\/i>, launched last year and aimed at enhancing the company\u2019s corporate value. AVI has published a detailed presentation on a dedicated website (www.AwakeningRohto.com<\/a>).<\/p>\n

<\/a>
<\/a><\/p>\n

\nSince initiating its investment in June 2024, AVI has sought to engage in constructive dialogue with Rohto, including through letters and presentations, with the objective of supporting sustainable corporate value enhancement. In April 2025, AVI publicly launched its campaign and put forward a range of recommendations to improve Rohto\u2019s corporate value. However, Rohto\u2019s share price performance has remained underwhelming. This reflects Rohto\u2019s continued investment in regenerative medicine without a clear path to profitability, as well as downward revisions to the performance of its Chinese medicine subsidiary, Eu Yan Sang, which was acquired at a significant premium in 2024.<\/p>\n

\nAVI has also identified governance concerns. Chairman Kunio Yamada, a fourth-generation member of the founding family, continues to oversee the medical business under a dispersed portfolio management approach that does not sufficiently align with the Tokyo Stock Exchange\u2019s guidance on management that is conscious of the cost of capital.<\/p>\n

\nIn light of these circumstances, AVI, as a shareholder committed to supporting sustainable corporate value enhancement, has decided to renew its public campaign following last year\u2019s initiative. Furthermore, AVI intends to submit a shareholder proposal to dismiss Chairman Kunio Yamada at Annual General Meeting scheduled for June 2026.<\/p>\n

\nKaz Sakai, Head of Japan Research at AVI, commented:<\/p>\n

\n\u201cWhile Rohto Pharmaceutical\u2019s core businesses, including its cosmetics and over-the-counter eye care segments, possess significant underlying value, continued investment in the regenerative medicine business, driven by the founding family\u2019s management philosophy, has again weighed on enterprise value this year.\u201d<\/i><\/p>\n

\n\u201cBy reviewing its business portfolio strategy and adopting a more focused management approach, together with enhancing capital discipline and shareholder communication in line with the Tokyo Stock Exchange\u2019s guidance, we believe Rohto\u2019s intrinsic value can be more fully realised.<\/i>\u201d<\/p>\n

Contacts<\/b> <\/p>\n

\nKimmberly Lau
\n
+44 (0)20 7659 4800
\n
info@assetvalueinvestors.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

LONDON–(BUSINESS WIRE)–Asset Value Investors Limited (\u201cAVI\u201d) today announced an update to its public campaign regarding Rohto Pharmaceutical Co., Ltd. (TSE: 4527, \u201cRohto\u201d), as a follow-up to its ongoing campaign, \u201cAwakening Rohto\u201d, launched last year and aimed at enhancing the company\u2019s corporate value. AVI has published a detailed presentation on a dedicated website (www.AwakeningRohto.com). Since initiating … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-63076","6":"format-standard","7":"category-industry"},"yoast_head":"\nAsset Value Investors (AVI) Urges Rohto Pharmaceutical to Focus on Core Businesses and Engage More Constructively with Shareholders - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/asset-value-investors-avi-urges-rohto-pharmaceutical-to-focus-on-core-businesses-and-engage-more-constructively-with-shareholders\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Asset Value Investors (AVI) Urges Rohto Pharmaceutical to Focus on Core Businesses and Engage More Constructively with Shareholders - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LONDON–(BUSINESS WIRE)–Asset Value Investors Limited (\u201cAVI\u201d) today announced an update to its public campaign regarding Rohto Pharmaceutical Co., Ltd. (TSE: 4527, \u201cRohto\u201d), as a follow-up to its ongoing campaign, \u201cAwakening Rohto\u201d, launched last year and aimed at enhancing the company\u2019s corporate value. AVI has published a detailed presentation on a dedicated website (www.AwakeningRohto.com). Since initiating ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/asset-value-investors-avi-urges-rohto-pharmaceutical-to-focus-on-core-businesses-and-engage-more-constructively-with-shareholders\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-07T23:03:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260507226752\/en\/2799285\/22\/AVI_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asset-value-investors-avi-urges-rohto-pharmaceutical-to-focus-on-core-businesses-and-engage-more-constructively-with-shareholders\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asset-value-investors-avi-urges-rohto-pharmaceutical-to-focus-on-core-businesses-and-engage-more-constructively-with-shareholders\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Asset Value Investors (AVI) Urges Rohto Pharmaceutical to Focus on Core Businesses and Engage More Constructively with Shareholders\",\"datePublished\":\"2026-05-07T23:03:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asset-value-investors-avi-urges-rohto-pharmaceutical-to-focus-on-core-businesses-and-engage-more-constructively-with-shareholders\\\/\"},\"wordCount\":368,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asset-value-investors-avi-urges-rohto-pharmaceutical-to-focus-on-core-businesses-and-engage-more-constructively-with-shareholders\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260507226752\\\/en\\\/2799285\\\/22\\\/AVI_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asset-value-investors-avi-urges-rohto-pharmaceutical-to-focus-on-core-businesses-and-engage-more-constructively-with-shareholders\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asset-value-investors-avi-urges-rohto-pharmaceutical-to-focus-on-core-businesses-and-engage-more-constructively-with-shareholders\\\/\",\"name\":\"Asset Value Investors (AVI) Urges Rohto Pharmaceutical to Focus on Core Businesses and Engage More Constructively with Shareholders - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asset-value-investors-avi-urges-rohto-pharmaceutical-to-focus-on-core-businesses-and-engage-more-constructively-with-shareholders\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asset-value-investors-avi-urges-rohto-pharmaceutical-to-focus-on-core-businesses-and-engage-more-constructively-with-shareholders\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260507226752\\\/en\\\/2799285\\\/22\\\/AVI_Logo.jpg\",\"datePublished\":\"2026-05-07T23:03:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asset-value-investors-avi-urges-rohto-pharmaceutical-to-focus-on-core-businesses-and-engage-more-constructively-with-shareholders\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asset-value-investors-avi-urges-rohto-pharmaceutical-to-focus-on-core-businesses-and-engage-more-constructively-with-shareholders\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asset-value-investors-avi-urges-rohto-pharmaceutical-to-focus-on-core-businesses-and-engage-more-constructively-with-shareholders\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260507226752\\\/en\\\/2799285\\\/22\\\/AVI_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260507226752\\\/en\\\/2799285\\\/22\\\/AVI_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asset-value-investors-avi-urges-rohto-pharmaceutical-to-focus-on-core-businesses-and-engage-more-constructively-with-shareholders\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Asset Value Investors (AVI) Urges Rohto Pharmaceutical to Focus on Core Businesses and Engage More Constructively with Shareholders\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Asset Value Investors (AVI) Urges Rohto Pharmaceutical to Focus on Core Businesses and Engage More Constructively with Shareholders - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/asset-value-investors-avi-urges-rohto-pharmaceutical-to-focus-on-core-businesses-and-engage-more-constructively-with-shareholders\/","og_locale":"en_US","og_type":"article","og_title":"Asset Value Investors (AVI) Urges Rohto Pharmaceutical to Focus on Core Businesses and Engage More Constructively with Shareholders - Pharma Trend","og_description":"LONDON–(BUSINESS WIRE)–Asset Value Investors Limited (\u201cAVI\u201d) today announced an update to its public campaign regarding Rohto Pharmaceutical Co., Ltd. (TSE: 4527, \u201cRohto\u201d), as a follow-up to its ongoing campaign, \u201cAwakening Rohto\u201d, launched last year and aimed at enhancing the company\u2019s corporate value. AVI has published a detailed presentation on a dedicated website (www.AwakeningRohto.com). Since initiating ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/asset-value-investors-avi-urges-rohto-pharmaceutical-to-focus-on-core-businesses-and-engage-more-constructively-with-shareholders\/","og_site_name":"Pharma Trend","article_published_time":"2026-05-07T23:03:24+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260507226752\/en\/2799285\/22\/AVI_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/asset-value-investors-avi-urges-rohto-pharmaceutical-to-focus-on-core-businesses-and-engage-more-constructively-with-shareholders\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/asset-value-investors-avi-urges-rohto-pharmaceutical-to-focus-on-core-businesses-and-engage-more-constructively-with-shareholders\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Asset Value Investors (AVI) Urges Rohto Pharmaceutical to Focus on Core Businesses and Engage More Constructively with Shareholders","datePublished":"2026-05-07T23:03:24+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/asset-value-investors-avi-urges-rohto-pharmaceutical-to-focus-on-core-businesses-and-engage-more-constructively-with-shareholders\/"},"wordCount":368,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/asset-value-investors-avi-urges-rohto-pharmaceutical-to-focus-on-core-businesses-and-engage-more-constructively-with-shareholders\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260507226752\/en\/2799285\/22\/AVI_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/asset-value-investors-avi-urges-rohto-pharmaceutical-to-focus-on-core-businesses-and-engage-more-constructively-with-shareholders\/","url":"https:\/\/pharma-trend.com\/en\/asset-value-investors-avi-urges-rohto-pharmaceutical-to-focus-on-core-businesses-and-engage-more-constructively-with-shareholders\/","name":"Asset Value Investors (AVI) Urges Rohto Pharmaceutical to Focus on Core Businesses and Engage More Constructively with Shareholders - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/asset-value-investors-avi-urges-rohto-pharmaceutical-to-focus-on-core-businesses-and-engage-more-constructively-with-shareholders\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/asset-value-investors-avi-urges-rohto-pharmaceutical-to-focus-on-core-businesses-and-engage-more-constructively-with-shareholders\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260507226752\/en\/2799285\/22\/AVI_Logo.jpg","datePublished":"2026-05-07T23:03:24+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/asset-value-investors-avi-urges-rohto-pharmaceutical-to-focus-on-core-businesses-and-engage-more-constructively-with-shareholders\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/asset-value-investors-avi-urges-rohto-pharmaceutical-to-focus-on-core-businesses-and-engage-more-constructively-with-shareholders\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/asset-value-investors-avi-urges-rohto-pharmaceutical-to-focus-on-core-businesses-and-engage-more-constructively-with-shareholders\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260507226752\/en\/2799285\/22\/AVI_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260507226752\/en\/2799285\/22\/AVI_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/asset-value-investors-avi-urges-rohto-pharmaceutical-to-focus-on-core-businesses-and-engage-more-constructively-with-shareholders\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Asset Value Investors (AVI) Urges Rohto Pharmaceutical to Focus on Core Businesses and Engage More Constructively with Shareholders"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/63076","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=63076"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/63076\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=63076"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=63076"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=63076"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}